

FW

Patent Application
Attorney Docket No. PC10343B

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 13th day of December, 2004

By

(Signature of person mailing)

Madeline Deveran

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Graham Maw, et al. :

APPLICATION NO.: 10/686,390 : Examiner: To Be Assigned

FILING DATE: October 15, 2003 : Group Art Unit: 1617

TITLE: Compounds for the Treatment of Female Sexual Dysfunction :

Hon. Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date:

Dec. 13, 2004

Pfizer Inc.

Patent Department, MS 8260-1611

Eastern Point Road


Groton, Connecticut 06340

(860) 715-4288

Martha G. Munchhof

Attorney for Applicant(s)

Reg. No. 47,811



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC10343B	SERIAL NO. 10/686,390
	APPLICANT Graham Nigel Maw, et al.	
	FILING DATE October 15, 2003	GROUP 1617

U.S. PATENT DOCUMENTS													
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	3	9	6	9	3	5	8	7-13-76	Amselem	260	294.8	
	US	4	8	4	0	8	1	8	7-7-88	Kruse	514	392	
	US	5	1	9	2	8	0	0	3-9-93	Barnish, et al	514	510	
	US	5	3	4	6	9	0	1	9-13-94	Bell et al Equivalent to RU2114114	514	258	
	US	5	8	7	7	2	1	6	3-2-99	Place et al	514	573	
	US	5	9	4	5	1	1	7	8-31-99	El-Rashidy, et al	424	430	
	US	6	7	3	4	1	8	6	5-11-04	Maw, et al Equivalent to Application US09/708,392	514	263.1	
	US	2003	0	0	2	7	8	2	4	2-6-03 Equivalent to RU2130776	514	234.5	
	US	2004	0	0	6	7	9	4	5	4-8-04 Equivalent to WO99/24433	514	243	

FOREIGN PATENT DOCUMENTS															
DOCUMENT NUMBER										DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES	NO
	JP	8	2	6	4	6	9	1		1996	JP No Equivalent	23	40		
	WO	9	1	0	4	0	3	2		4-4-91	PCT	A61K 31	70		
	WO	0	2	0	7	9	1	4 3		10-10-02	PCT	C07C	235/82		
	WO	0	2	0	2	5	1	3		1-10-02	PCT	C07C	237/22		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)															
			Zusman, et al., <u>American Journal of Cardiology</u> , "Overall Cardiovascular Profile of Sildenafil Citrate, Vol 83, pp. 35c-44c (1999)												
			Spillantini, et al., <u>Biochemical Pharmacology</u> , "Characterization of Endopetidase 3.4.24.11 ("Enkephalinase") Activity In Human Plasma and Cerebrospinal Fluid", Vol 39(8) pp. 1353-1356 (1990)												

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. PC10343B	SERIAL NO. 10/686,390
			APPLICANT Graham Nigel Maw, et al.	
			FILING DATE October 15, 2003	GROUP 1617
		Seiichiro, et al., <u>Chemical Abstract</u> , "Effect of ritodrine hydrochlorid on uterine activity and maternal and fetal circulation in the pregnant sheep", Vol. 100(11), pg540 (1984)		
		Dubertret, et al., <u>Chemical Abstract</u> , "Fluorescence detection of an 8-methoxypsoralen metabolite in human interstitial fluid" Vol. 97(151), pg. 712, (1982)		
		Yandle, et al., <u>Clinical Chemistry</u> , "Assay of Endopeptidase-24.11 Activity in Plasma Applied to In Vivo Studies of Eendopeptidase Inhibitors", Vol. 38(9), pp. 1785-1791, (1992)		
		Wayman, et al., <u>International Journal of Impotence Research</u> , "10 th World Congress of the International Society for Sexual and Impotence Research", Vol 14(3), page S-7, (2002)		
		Wayman, et al., <u>International Society for the Study of Women's Sexual Health Annual Meeting</u> , "Evidence that Neutral Endopeptidase is Involved in the Regulation of Female Genital Blood Flow, Page 34 Program Book, October 10-13, 2002, (plus PowerPoint Presentation)		
		Burnett, et al., <u>Journal of Hypertension</u> , "Vasoptidase inhibition: a new concept in blood pressure management", Vol 17, pp. S37-S43 (1999)		
		Fink, et al., <u>Journal of Medical Chemistry</u> , "Mercaptoacyl Dipeptides as Orally Active Dual Inhibitors of Angiotensin-Converting enzyme and Neutral Endopeptidase", Vol. 39, pp. 3158-3168, (1996)		
		Zhang, et al., <u>Peptides</u> , "ELISA for the Neuropeptide Degrading Endopeptidase 3.4.24.11 in Human Serum and Leukocytes, Vol 15(5), pp. 843-848, (1994)		
EXAMINER			DATE CONSIDERED	